Clinical outcomes in elderly patients with advanced non-small cell lung cancer: Results from ARIES, a bevacizumab observational cohortstudy

A. J. Wozniak, M. P. Kosty, Mohammad Jahanzeb, J. R. Brahmer, D. R. Spigel, L. Leon, S. Fish, E. D. Flick, S. J. Hazard, T. J. Lynch

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Aims: Retrospective analyses from first-line clinical studies in advanced non-small cell lung cancer (NSCLC) have reported conflicting results on progression-free survival (PFS) and overall survival benefits with the addition of bevacizumab to chemotherapy in elderly patients. Here we report effectiveness and safety outcomes by age subgroup for patients with NSCLC in the ARIES observational cohort study. Materials and Methods: ARIES enrolled patients with advanced non-squamous NSCLC who received first-line bevacizumab-containing treatment per physician's choice. Kaplan-Meier estimates were used to calculate medians and 95% confidence intervals for PFS and overall survival for patients aged <65, ≥65, <75 and ≥75 years. Results: In total, 1967 patients receiving first-line treatment with bevacizumab and chemotherapy were enrolled. The median PFS and overall survival values were 6.4 (95% confidence interval=6.0-6.8) and 14.2 (95% confidence interval=12.7-15.2) months for patients aged <65 years, respectively, and 6.8 (95% confidence interval=6.3-7.0) and 12.1 (95% confidence interval=11.4-13.1) months for patients ≥65 years, respectively. For patients <75 years, the median PFS and overall survival values were 6.6 (95% confidence interval=6.3-6.9) and 13.5 (95% confidence interval=12.6-14.5) months, respectively, and 6.6 (95% confidence interval=5.9-7.1) and 11.6 (95% confidence interval=10.0-12.5) months, respectively, for patients ≥75 years. Incidence proportions of bevacizumab-associated adverse events were generally similar across all age groups. Conclusions: Data from the ARIES study suggest that treatment with bevacizumab in combination with chemotherapy is a viable first-line treatment option for elderly bevacizumab-eligible patients with advanced non-squamous NSCLC.

Original languageEnglish (US)
Pages (from-to)187-196
Number of pages10
JournalClinical Oncology
Volume27
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Confidence Intervals
Disease-Free Survival
Survival
Bevacizumab
Drug Therapy
Kaplan-Meier Estimate
Therapeutics
Combination Drug Therapy
Observational Studies
Cohort Studies
Age Groups
Physicians
Safety
Incidence

Keywords

  • Bevacizumab
  • Chemotherapy
  • Elderly
  • NSCLC
  • Observational cohort study

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Clinical outcomes in elderly patients with advanced non-small cell lung cancer : Results from ARIES, a bevacizumab observational cohortstudy. / Wozniak, A. J.; Kosty, M. P.; Jahanzeb, Mohammad; Brahmer, J. R.; Spigel, D. R.; Leon, L.; Fish, S.; Flick, E. D.; Hazard, S. J.; Lynch, T. J.

In: Clinical Oncology, Vol. 27, No. 4, 01.04.2015, p. 187-196.

Research output: Contribution to journalArticle

Wozniak, AJ, Kosty, MP, Jahanzeb, M, Brahmer, JR, Spigel, DR, Leon, L, Fish, S, Flick, ED, Hazard, SJ & Lynch, TJ 2015, 'Clinical outcomes in elderly patients with advanced non-small cell lung cancer: Results from ARIES, a bevacizumab observational cohortstudy', Clinical Oncology, vol. 27, no. 4, pp. 187-196. https://doi.org/10.1016/j.clon.2014.12.002
Wozniak, A. J. ; Kosty, M. P. ; Jahanzeb, Mohammad ; Brahmer, J. R. ; Spigel, D. R. ; Leon, L. ; Fish, S. ; Flick, E. D. ; Hazard, S. J. ; Lynch, T. J. / Clinical outcomes in elderly patients with advanced non-small cell lung cancer : Results from ARIES, a bevacizumab observational cohortstudy. In: Clinical Oncology. 2015 ; Vol. 27, No. 4. pp. 187-196.
@article{d5067cf2a98247d288b5f431d2ce1942,
title = "Clinical outcomes in elderly patients with advanced non-small cell lung cancer: Results from ARIES, a bevacizumab observational cohortstudy",
abstract = "Aims: Retrospective analyses from first-line clinical studies in advanced non-small cell lung cancer (NSCLC) have reported conflicting results on progression-free survival (PFS) and overall survival benefits with the addition of bevacizumab to chemotherapy in elderly patients. Here we report effectiveness and safety outcomes by age subgroup for patients with NSCLC in the ARIES observational cohort study. Materials and Methods: ARIES enrolled patients with advanced non-squamous NSCLC who received first-line bevacizumab-containing treatment per physician's choice. Kaplan-Meier estimates were used to calculate medians and 95{\%} confidence intervals for PFS and overall survival for patients aged <65, ≥65, <75 and ≥75 years. Results: In total, 1967 patients receiving first-line treatment with bevacizumab and chemotherapy were enrolled. The median PFS and overall survival values were 6.4 (95{\%} confidence interval=6.0-6.8) and 14.2 (95{\%} confidence interval=12.7-15.2) months for patients aged <65 years, respectively, and 6.8 (95{\%} confidence interval=6.3-7.0) and 12.1 (95{\%} confidence interval=11.4-13.1) months for patients ≥65 years, respectively. For patients <75 years, the median PFS and overall survival values were 6.6 (95{\%} confidence interval=6.3-6.9) and 13.5 (95{\%} confidence interval=12.6-14.5) months, respectively, and 6.6 (95{\%} confidence interval=5.9-7.1) and 11.6 (95{\%} confidence interval=10.0-12.5) months, respectively, for patients ≥75 years. Incidence proportions of bevacizumab-associated adverse events were generally similar across all age groups. Conclusions: Data from the ARIES study suggest that treatment with bevacizumab in combination with chemotherapy is a viable first-line treatment option for elderly bevacizumab-eligible patients with advanced non-squamous NSCLC.",
keywords = "Bevacizumab, Chemotherapy, Elderly, NSCLC, Observational cohort study",
author = "Wozniak, {A. J.} and Kosty, {M. P.} and Mohammad Jahanzeb and Brahmer, {J. R.} and Spigel, {D. R.} and L. Leon and S. Fish and Flick, {E. D.} and Hazard, {S. J.} and Lynch, {T. J.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.clon.2014.12.002",
language = "English (US)",
volume = "27",
pages = "187--196",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Clinical outcomes in elderly patients with advanced non-small cell lung cancer

T2 - Results from ARIES, a bevacizumab observational cohortstudy

AU - Wozniak, A. J.

AU - Kosty, M. P.

AU - Jahanzeb, Mohammad

AU - Brahmer, J. R.

AU - Spigel, D. R.

AU - Leon, L.

AU - Fish, S.

AU - Flick, E. D.

AU - Hazard, S. J.

AU - Lynch, T. J.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Aims: Retrospective analyses from first-line clinical studies in advanced non-small cell lung cancer (NSCLC) have reported conflicting results on progression-free survival (PFS) and overall survival benefits with the addition of bevacizumab to chemotherapy in elderly patients. Here we report effectiveness and safety outcomes by age subgroup for patients with NSCLC in the ARIES observational cohort study. Materials and Methods: ARIES enrolled patients with advanced non-squamous NSCLC who received first-line bevacizumab-containing treatment per physician's choice. Kaplan-Meier estimates were used to calculate medians and 95% confidence intervals for PFS and overall survival for patients aged <65, ≥65, <75 and ≥75 years. Results: In total, 1967 patients receiving first-line treatment with bevacizumab and chemotherapy were enrolled. The median PFS and overall survival values were 6.4 (95% confidence interval=6.0-6.8) and 14.2 (95% confidence interval=12.7-15.2) months for patients aged <65 years, respectively, and 6.8 (95% confidence interval=6.3-7.0) and 12.1 (95% confidence interval=11.4-13.1) months for patients ≥65 years, respectively. For patients <75 years, the median PFS and overall survival values were 6.6 (95% confidence interval=6.3-6.9) and 13.5 (95% confidence interval=12.6-14.5) months, respectively, and 6.6 (95% confidence interval=5.9-7.1) and 11.6 (95% confidence interval=10.0-12.5) months, respectively, for patients ≥75 years. Incidence proportions of bevacizumab-associated adverse events were generally similar across all age groups. Conclusions: Data from the ARIES study suggest that treatment with bevacizumab in combination with chemotherapy is a viable first-line treatment option for elderly bevacizumab-eligible patients with advanced non-squamous NSCLC.

AB - Aims: Retrospective analyses from first-line clinical studies in advanced non-small cell lung cancer (NSCLC) have reported conflicting results on progression-free survival (PFS) and overall survival benefits with the addition of bevacizumab to chemotherapy in elderly patients. Here we report effectiveness and safety outcomes by age subgroup for patients with NSCLC in the ARIES observational cohort study. Materials and Methods: ARIES enrolled patients with advanced non-squamous NSCLC who received first-line bevacizumab-containing treatment per physician's choice. Kaplan-Meier estimates were used to calculate medians and 95% confidence intervals for PFS and overall survival for patients aged <65, ≥65, <75 and ≥75 years. Results: In total, 1967 patients receiving first-line treatment with bevacizumab and chemotherapy were enrolled. The median PFS and overall survival values were 6.4 (95% confidence interval=6.0-6.8) and 14.2 (95% confidence interval=12.7-15.2) months for patients aged <65 years, respectively, and 6.8 (95% confidence interval=6.3-7.0) and 12.1 (95% confidence interval=11.4-13.1) months for patients ≥65 years, respectively. For patients <75 years, the median PFS and overall survival values were 6.6 (95% confidence interval=6.3-6.9) and 13.5 (95% confidence interval=12.6-14.5) months, respectively, and 6.6 (95% confidence interval=5.9-7.1) and 11.6 (95% confidence interval=10.0-12.5) months, respectively, for patients ≥75 years. Incidence proportions of bevacizumab-associated adverse events were generally similar across all age groups. Conclusions: Data from the ARIES study suggest that treatment with bevacizumab in combination with chemotherapy is a viable first-line treatment option for elderly bevacizumab-eligible patients with advanced non-squamous NSCLC.

KW - Bevacizumab

KW - Chemotherapy

KW - Elderly

KW - NSCLC

KW - Observational cohort study

UR - http://www.scopus.com/inward/record.url?scp=84924679379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924679379&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2014.12.002

DO - 10.1016/j.clon.2014.12.002

M3 - Article

C2 - 25576353

AN - SCOPUS:84924679379

VL - 27

SP - 187

EP - 196

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 4

ER -